Balcom Alexandra
SEC insider (Form 3/4/5 filer). CIK 0001862147. Chief Financial Officer at Nuvalent, Inc. (NUVL) and 1 other issuer. 106 reported Form 4/5 transactions since Sep 2024; latest on Jul 15, 2026. Located in CAMBRIDGE, MA.
Companies Balcom Alexandra has filed insider reports for
- Nuvalent, Inc. (NUVL): Officer, Chief Financial Officer
- CRESCENT BIOPHARMA, INC. (CBIO): Director
Balcom Alexandra
CIK: 0001862147
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (106 total)
- Jul 15, 2026NUVL
Nuvalent, Inc.
Tender OfferDirect44.4K shares at avg. $124.00$5.5M - Jul 15, 2026NUVL
Nuvalent, Inc.
DispositionDirect14.4K shares- - Jul 15, 2026NUVL
Nuvalent, Inc.
AwardDirect14.4K shares- - Jul 15, 2026NUVL
Nuvalent, Inc.
DispositionDirect41.1K shares- - Jul 1, 2026NUVL
Nuvalent, Inc.
ExerciseDirect6K shares at avg. $18.93$114K - Jul 1, 2026NUVL
Nuvalent, Inc.
ExerciseDirect5.4K shares at avg. $6.89$37K - Jul 1, 2026NUVL
Nuvalent, Inc.
SaleDirect11.4K shares at avg. $123.58$1.4M - Jun 2, 2026CBIO
CRESCENT BIOPHARMA, INC.
AwardDirectStock Option (Right to Buy)
11.1K shares- - Jun 1, 2026NUVL
Nuvalent, Inc.
SaleDirect279 shares at avg. $101.79$28K - Jun 1, 2026NUVL
Nuvalent, Inc.
SaleDirect900 shares at avg. $97.68$88K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 15, 2026 |  NUVL Nuvalent, Inc. | Tender Offer | 44,433 | $124.00 | $5,509,692 | Direct |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | Disposition | 14,350 | - | $0 | Direct |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | Award | 14,350 | - | $0 | Direct |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | Disposition | 41,100 | - | $0 | Direct |
| Jul 1, 2026 | NUVL Nuvalent, Inc. | Exercise | 6,046 | $18.93 | $114,451 | Direct |
| Jul 1, 2026 | NUVL Nuvalent, Inc. | Exercise | 5,384 | $6.89 | $37,096 | Direct |
| Jul 1, 2026 | NUVL Nuvalent, Inc. | Sale | 11,430 | $123.58 | $1,412,519 | Direct |
| Jun 2, 2026 |  CBIO CRESCENT BIOPHARMA, INC. | Award Stock Option (Right to Buy) | 11,050 | - | - | Direct |
| Jun 1, 2026 | NUVL Nuvalent, Inc. | Sale | 279 | $101.79 | $28,399 | Direct |
| Jun 1, 2026 | NUVL Nuvalent, Inc. | Sale | 900 | $97.68 | $87,912 | Direct |
1-10 of 106 transactions